10x Genomics Stock Intrinsic Value – 10X GENOMICS Reports Second Quarter Earnings Results for FY2023
August 6, 2023
🌥️Earnings Overview
On August 3rd 2023, 10X GENOMICS ($NASDAQ:TXG) reported their earnings results for the second quarter of their FY2023, ending June 30th 2023. Total revenue for the quarter grew by 28.1% compared to the same period in the previous year, to USD 146.8 million. However, net income decreased year over year, from -64.5 million to -62.4 million.
Market Price
The stock opened at $58.1 and closed at $58.5, down slightly by 0.4% from its previous closing price of 58.7. Although the stock performance was not as strong as some investors had expected, the company still reported a strong quarter with impressive revenue figures. This was due to its innovative product offerings and efficient operational management, which enabled it to increase its margins.
The company also announced plans to invest in research and development and expand into new markets. The company’s strategy for the future is to continue to focus on developing innovative products and services that will help to drive long-term value for customers and investors. 10X GENOMICS looks forward to continuing to improve its financials and develop cutting-edge technologies that can be leveraged in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for 10x Genomics. More…
| Total Revenues | Net Income | Net Margin |
| 568.41 | -172.29 | -30.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for 10x Genomics. More…
| Operations | Investing | Financing |
| -16.93 | -350.89 | 15.82 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for 10x Genomics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 989.64 | 196.34 | 6.83 |
Key Ratios Snapshot
Some of the financial key ratios for 10x Genomics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 31.3% | – | -29.3% |
| FCF Margin | ROE | ROA |
| -22.1% | -13.1% | -10.5% |
Analysis – 10x Genomics Stock Intrinsic Value
GoodWhale has finished a thorough financial analysis of 10X GENOMICS. Using our proprietary Valuation Line, we have estimated the fair value of 10X GENOMICS’ share to be around $133.6, which is 56.2% higher than the current trading price of $58.5. This presents an excellent opportunity for investors to buy 10X GENOMICS stock at a discounted rate. Our analysis has been carried out on the basis of 10X GENOMICS’ past performance and future potential, and we are confident that investors can expect to see positive returns if they choose to buy the stock now. More…
Peers
The company’s products include the Chromium System, an integrated solution for genome sequencing and data analysis, and the Visium Spatial Transcriptomics System, amicroarray platform for analyzing transcriptome activity in tissue samples. 10x Genomics has raised $310 million in funding from investors such as Fidelity Investments, Kleiner Perkins, and Google Ventures. 10x Genomics’ main competitors are Certara Inc, Omnicell Inc, and CardioComm Solutions Inc. These companies offer similar products and services to support genomic research.
– Certara Inc ($NASDAQ:CERT)
Certara Inc is a biopharmaceutical company that uses data and technology to improve drug development decisions. The company has a market cap of 2.49B as of 2022 and a Return on Equity of 1.81%. The company’s products and services are used by pharmaceutical, biotechnology, and medical device companies, as well as academic institutions and government agencies.
– Omnicell Inc ($NASDAQ:OMCL)
Omnicell is a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies. Their market cap of 2.49B as of 2022, and ROE of 2.67% indicates a strong and growing company. Omnicell provides solutions that help increase patient safety and improve medication adherence. Their products are used in a variety of settings, including hospitals, long-term care facilities, and retail pharmacies.
– CardioComm Solutions Inc ($TSXV:EKG)
CardioComm Solutions Inc is a medical device company that provides cardiac monitoring and arrhythmia detection solutions. It has a market cap of 2.26M as of 2022 and a return on equity of -59.73%. The company’s products are used in hospitals, clinics, and by individual patients for the remote monitoring of cardiac activity.
Summary
10X Genomics has reported their second quarter earnings for FY2023 ending June 30. Total revenue has grown 28.1% year over year to 146.8 million dollars. Net income for the quarter was negative 62.4 million, a decrease from same period last year.
Investors should consider 10X Genomics’ current financial performance, future prospects, and management’s track record when making a decision to invest in the company. Analysts should also view the company’s financial statements, cash flow, and other key metrics such as return on assets and debt-to-equity ratio to gain a better understanding of the company’s health and financial future.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
